Albireo Pharma Stock Forecast, Price & News

+0.31 (+0.97 %)
(As of 04/13/2021 11:51 AM ET)
Today's Range
Now: $32.25
50-Day Range
MA: $35.28
52-Week Range
Now: $32.25
Volume1,079 shs
Average Volume172,677 shs
Market Capitalization$616.43 million
P/E RatioN/A
Dividend YieldN/A
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Albireo Pharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALBO
Phone(857) 254-5555
Year FoundedN/A



Sales & Book Value

Annual Sales$9.64 million
Book Value$7.34 per share


Net Income$-62,720,000.00
Net Margins-751.53%


Market Cap$616.43 million
Next Earnings Date5/6/2021 (Estimated)


Albireo Pharma (NASDAQ:ALBO) Shares Gap Up to $31.94
April 13, 2021 |
See More Headlines


Overall MarketRank

1.53 out of 5 stars

Medical Sector

471st out of 2,016 stocks

Pharmaceutical Preparations Industry

226th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.31 (+0.97 %)
(As of 04/13/2021 11:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

Is Albireo Pharma a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Albireo Pharma?

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Albireo Pharma

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.90) by $0.60. The biopharmaceutical company had revenue of $2.72 million for the quarter, compared to analysts' expectations of $2.23 million. Albireo Pharma had a negative trailing twelve-month return on equity of 71.22% and a negative net margin of 751.53%.
View Albireo Pharma's earnings history

How has Albireo Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALBO stock has increased by 84.6% and is now trading at $32.55.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALBO?

8 analysts have issued 1-year price objectives for Albireo Pharma's stock. Their forecasts range from $65.00 to $82.00. On average, they anticipate Albireo Pharma's stock price to reach $72.00 in the next year. This suggests a possible upside of 121.2% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 58, Pay $838.51k)
  • Dr. Patrick T. Horn, Chief Medical Officer (Age 66, Pay $588.46k)
  • Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 53, Pay $469.19k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson, Chief Scientific Officer & MD (Sweden) and Co-Founder (Age 57)
  • Mr. Simon N.R. Harford, CFO & Treasurer (Age 60)
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 46)
  • Ms. Michelle Graham, Chief HR Officer (Age 54)
  • Dr. Kristina TorfgÃ¥rd, VP & Global Project Head
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 69)

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Chicago Capital LLC (3.59%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma

Which major investors are buying Albireo Pharma stock?

ALBO stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $32.55.

How much money does Albireo Pharma make?

Albireo Pharma has a market capitalization of $622.16 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 90 workers across the globe.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is

Where are Albireo Pharma's headquarters?

Albireo Pharma is headquartered at 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.